Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)

Academic Article
Publication Date:
2022
Short description:
Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module) / Ramage, J.K., Friend, E., Randell, J., King, B., Fernandez Ortega, P., Mcnamara, M.G., Kaltsas, G., Falconi, M., Cwikla, J., Capdevila, J., Grozinsky-Glasberg, S., Mandair, D., Gamper, E., Srirajaskanthan, R., O Weickert, M., Gray, D.. - In: JOURNAL OF NEUROENDOCRINOLOGY. - ISSN 0953-8194. - 34:4(2022). [10.1111/jne.13097]
abstract:
Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examined in detail. EORTC (European Organisation for Research and Treatment of Cancer) guidelines were followed in phases 1–3 to produce a potential module of questions usable for trials in panNET, focusing on three common types of panNET. For two less common types, a list of symptoms was constructed. Following an extensive literature search and phase 1a interviews with patients and healthcare workers, a long list of potential issues (169) was obtained. This list was shown to 12 patients from three countries in phase 1b interviews to check that no items were missed. The list was reduced to 57 issues. The list of issues was converted to questions, mainly from existing validated questions within the EORTC item library. The list of questions was then used in a phase 3 international study in eight countries using seven languages. A provisional module of 24 items is presented for use in nonfunctioning panNET, gastrinoma and insulinoma. This module increases knowledge concerning QoL in this condition and may be a useful adjunct in clinical trials. A phase 4 trial is being considered for validation of this questionnaire.
Iris type:
1.1 Articolo in rivista
Keywords:
gastrinoma; insulinoma; pancreatic neoplasm; pancreatic neuroendocrine tumour; quality of life
List of contributors:
Ramage, J. K.; Friend, E.; Randell, J.; King, B.; Fernandez Ortega, P.; Mcnamara, M. G.; Kaltsas, G.; Falconi, M.; Cwikla, J.; Capdevila, J.; Grozinsky-Glasberg, S.; Mandair, D.; Gamper, E.; Srirajaskanthan, R.; O Weickert, M.; Gray, D.
Authors of the University:
FALCONI MASSIMO
Handle:
https://iris.unisr.it/handle/20.500.11768/137161
Published in:
JOURNAL OF NEUROENDOCRINOLOGY
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.7.2.0